Grafix® DFU: Open-Label Extension Option to Evaluate Safety & Efficacy of Grafix® for Chronic Diabetic Foot Ulcers

Diabetic Foot Ulcers Clinical Trial

— DFU  

Official title:

A Multicenter, Adaptive Design, Randomized, Single-Blind Study With an Open-Label Extension Option to Further Evaluate the Safety and Efficacy of Grafix® for the Treatment of Chronic Diabetic Foot Ulcers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01596920
• Other study ID #: Osiris 302
• Status: Completed
• Phase: Phase 4
• First received: March 14, 2012
• Last updated: April 7, 2014
• Start date: April 2012
• Est. completion date: March 2014

Study information

• Verified date: April 2014
• Source: Osiris Therapeutics
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The primary objective of the present study is to further establish in a randomized controlled trial, the safety and efficacy of weekly Grafix® administration versus control in patients with chronic diabetic foot ulcers. The primary endpoint is complete wound closure of the index wound, defined as 100% re-epithelialization as determined by the Investigator.

Grafix® is a product regulated for use in the US by the FDA as a Human Cellular and Tissue Based Product (HCT/P) under Title 21 CFR Part 1271.

Description:

The treatment indication is for chronic, diabetic foot ulcers (DFUs) between 1cm2 and 15cm2 located below the malleoli on the plantar or dorsal surface of the foot. Patients must have confirmed Type I or Type II Diabetes.

Patients will receive treatment every week for 12 weeks duration in the Single-Blind Treatment phase of the trial.

Patients who receive Grafix® or control will be evaluated for primary efficacy up to 84 days, and for safety and wound re-occurrence for 84 days after wound closure. Patients in the control group whose wounds are not closed at the end of treatment may be offered Grafix® in an Open-Label Treatment phase. The Open-Label Treatment phase can last up to an additional 84 days.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 97
• Est. completion date: March 2014
• Est. primary completion date: August 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Between 18 years and 80 years of age inclusive, as of the date of screening

2. Confirmed diagnosis of Type I or Type II Diabetes

3. An Index Ulcer defined as chronic (presence of wound for > 4 weeks) but not present for more than 52 weeks at the Screening Visit

4. Index Ulcer is located below the malleoli on the plantar or dorsal surface of the foot

5. The Index Ulcer is between 1cm2 and 15 cm2 at the Screening Visit

6. The Index Ulcer extends into the dermis or subcutaneous tissue without evidence of exposed muscle, tendon, bone, or joint capsule

7. Wound is free of necrotic debris

8. Patient has adequate circulation to the foot as documented by either:

• Ankle Brachial Index (ABI) > 0.70 and < 1.30, or

• In patients with non-compressible ankle vessels defined as an ABI = 1.30, a Toe Brachial Index (TBI) = 0.50

• In patients with non-compressible ankle vessels defined as an ABI = 1.30 and TBI cannot be performed (e.g., toe is absent, wounds are present, or site cannot perform a TBI), a Doppler waveform in the posterior tibial or dorsalis pedis arteries at the ankle consistent with adequate flow in the foot (biphasic or triphasic) and other diagnostic confirmation of adequate flow (e.g., duplex imaging, normal pulse volume recording [PVR] testing).

Exclusion Criteria:

1. Index Ulcer is of non-diabetic pathophysiology

2. Gangrene is present on any part of the affected foot

3. Index Ulcer is over an active Charcot deformity

4. The longest dimension of the Index Ulcer exceeds 5 cm at the Baseline Visit

5. Patient is currently receiving dialysis

6. Patient has a glycated hemoglobin A1c (HbA1c) level of > 12%

7. Chronic oral steroid use > 7.5 mg daily

8. Requiring intravenous (IV) antibiotics to treat the index wound infection

9. Patient has an ulcer within 15cm of the Index Ulcer identified for study consideration

10. Patient is receiving oral or parenteral corticosteroids, immunosuppressive or cytotoxic agents

11. Patient is Human Immunodeficiency Virus (HIV) positive or has Acquired Immune Deficiency Syndrome (AIDS)

12. Current evidence of osteomyelitis, cellulitis, or other evidence of infection including fever or pus drainage from the wound site

13. Patient has active malignancy other than non-melanoma skin cancer

14. Patient's Index Ulcer has decreased by = 30% during 1-week screening period as determined by criteria provided by the Wound Core Lab

15. Patient's random blood sugar is > 450 mg/dl at screening

16. Patient has untreated alcohol or substance abuse at the time of screening

17. Pregnant women

18. Patient is currently enrolled or participated in another investigational device, drug, or biological trial within 60 days of screening

19. Patient has allergy to primary or secondary dressing materials used in this trial

20. Patient has had within the last 30 days, or is currently undergoing, or is planning for wound treatments with enzymes, growth factors, living skin, dermal substitutes or other advanced biological therapies

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetic Foot
• Diabetic Foot Ulcers
• Foot Ulcer
• Ulcer

Intervention

Other:
• Tissue
Allograft Tissue Cellular Repair Matrix
• Control
Non-adherent Dressing

Locations

Country	Name	City	State
United States	Blair Orthopedics Associates, Inc	Altoona	Pennsylvania
United States	UNC at Chapel Hill	Chapel Hill	North Carolina
United States	Cleveland Clinic	Cleveland	Ohio
United States	Ohio Health Research Institute	Columbus	Ohio
United States	UT Southwestern Medical Center at Dallas	Dallas	Texas
United States	Duke University Medical Center	Durham	North Carolina
United States	ILD Laser and Research Center	Encinitas	California
United States	Aiyan Diabetes Center	Evans	Georgia
United States	Clinical Trials of Arizona, Inc.	Glendale	Arizona
United States	Nature Coast Clinical Research	Inverness	Florida
United States	River City Clinical Research	Jacksonville	Florida
United States	Institute for Advanced Wound Care at Baptist Medical	Montgomery	Alabama
United States	Clincal Trials of Texas, Inc.	San Antonio	Texas
United States	Ocean County Foot and Ankle Surgical Associates	Toms River	New Jersey
United States	Omega Medical Research	Warwick	Rhode Island

Sponsors (1)

Lead Sponsor	Collaborator
Osiris Therapeutics

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Complete closure of the index wound, defined as 100% re-epithelialization as determined by the Investigator, anytime up to the Day 84 Visit		Up to 84 days	No
Secondary	Time to initial wound closure		Up to 84 days after the Single-Blind Treatment Visits	No
Secondary	number of patients with >50% reduction in wound size by Day 28		Up to 84 days after the Single-Blind Treatment Visits	No
Secondary	number of applications of Grafix® versus control		Up to 84 days after the Single-Blind Treatment Visits	No
Secondary	number of re-occurrences of index wound post-healing		Up to 84 days after the Single-Blind Treatment Visits	No
Secondary	percent of wounds achieving complete closure		Up to 84 days after the Single-Blind Treatment Visits	No